Europe/India/Near East USA Asia
Bachem AG Bachem Americas, Inc. Bachem Japan K.K.
Hauptstrasse 144 3132 Kashiwa Street AREA Shinagawa, 13F
4416 Bubendorf - Switzerland Torrance, CA 90505 - USA Tokyo 108-0075 - Japan
Tel +41 58 595 2021 Tel +1 888 422 2436 Tel +81 3 4405 3141
Fax +41 58 595 2040 Tel +1 888 4BACHEM Email sales.jp@bachem.com
Email sales.ch@bachem.com Fax +1 310 539 9428  
  E-mail sales.us@bachem.com  

DETAIL

Neuren

09. May 2007
Neuren and Bachem continue close collaboration on Glypromate® - Neuren’s lead product now in phase III

Bachem and Neuren Pharmaceuticals Limited today announced to continue their close collaboration on Glypromate®, Neuren’s lead product currently under development for the prevention of cognitive impairment following major cardiac surgery. During the long-standing partnership from pre-clinical development up to today, Bachem has provided Neuren the active ingredient and complete regulatory documentation on its GMP production. Recently the US American regulatory agency, FDA, has approved Neuren’s investigational drug application (IND) and authorized the company to proceed with a phase III trial on Glypromate®. This decision brings the partnership between Bachem and Neuren into a new dimension. The phase III clinical trial requires substantial higher quantities of the developmental compound and initial preparation for securing supply for a potential market launch, which is actually planned for 2010.

 

Press Release